The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
This thread is surprising me. Yes there’s been no real news, but unless I’ve missed something hugely negative over the last month or so this was the plan…
· Target spud date of January / February 2023 - subject to successful completion of rig audit and contract agreement;
That’s a good few months off yet. The rig has been cleared. It’s just a matter of waiting for things to be put in place hopefully. Or did I miss yet another screw up that everyone is getting het up about?
It’s a long day so here’s a prediction just for fun. The financial RNS arrives at the end of the day so little time to react. Then we have a Monday morning RNS to follow it up. Maybe.
Hopefully it arrives earlier rather than later though.
@Helx2 - It seems 'planned 2022' has now turned into 'Intent' for Jan/Feb 2023. As you can see now, my point was correct. It's important to scrutinise the wording. Whether that be Jan/Feb or later this has to happen next year. Hopefully as early as possible and with a 'warm' drill that's been checked and maintained to perfection.
To save you talking to yourself over and over… that may be so. But there have been signs of change and moves that put Synairgen firmly in a working relationship with some big pharma companies. AZ were listed as being part of the recent study before it was amended. They must have been sniffing around in the first place for their name to have been put there. It has seemed pounded to death in recent times for sure. But they have always been confident. And is seems never more so at the moment. Interesting times ahead.
The slight change of language in the last RNS to ‘future drilling campaign’ was a bit of a red flag. Hopefully it will happen this year, but they may have been setting the language incase it didn’t happen. Either way, it should definitely happen by this time 2023 as they’ll have everything in place. Surely.
This is not about the SP. It’s about what comes out of the other end of the trial and the people we are involved with. That’ll be far more valuable in the long run.
Not just Janssen…
Funder:
This trial is funded by Janssen Pharmaceuticals and AstraZeneca, with support in kind from Synairgen Ltd.
Funder:
This trial is funded by Janssen Pharmaceuticals and AstraZeneca, with support in kind from Synairgen Ltd.
Like I said on the First IM thread…
“All Parties are fully committed to the formal completion of the IM transaction, following each parties final internal approval process which, with reference to the Client Company (a global manufacturer), is planned for next week.”
So, depending on how you choose to read that could mean the transaction, or the internal approval process. Maybe? There’s plenty of time left today. Here’s hoping.
Evening MisterGreen, yes exactly. Not super clear, but hopefully something good will come in the not too distant future. I think we’ve all learned to expect something different from all the overly positive hype that seems to come just before a deadline or time line. The cynic in me says a lot of that hype is funded. We’ll see what transpires soon. Hopefully it’ll be the beginning of the good times.
@MisterGreen - For clarity, the RNS on Friday 29th July said this:
“All Parties are fully committed to the formal completion of the IM transaction, following each parties final internal approval process which, with reference to the Client Company (a global manufacturer), is planned for next week.”
So, depending on how you choose to read that could mean the transaction, or the internal approval process. Maybe? We’ll see.
I’m really hoping all this positivity is correct. There’s certainly a deadline coming and surely that means some news.
There is though, always the same kind of pattern in the days leading up to SYME deadlines. Talk of things taking off. Rocketing. The news we’ve all been waiting for. Don’t get me wrong, I want to hear something amazing happen and for this share to take off, but the fact of the matter so far has been over a year of disappointment and letdown.
This share has a long way to recover. Sitting back and watching what happens on this impending launch pad might be the safest approach. After all, there is of course a placing on offer that’s currently lower than where we are.